Werewolf Therapeutics, Inc. (HOWL): Nasdaq/NYSE listing notice — Werewolf Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

Werewolf Therapeutics, Inc.

Notice dated Feb 4, 2026: bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (to Aug 3, 2026) to regain compliance.
To comply, closing bid must be at least $1.00 for 10 consecutive business days.
If initial period fails, may transfer to Nasdaq Capital Market for additional 180 days.
Company monitoring options but no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Werewolf Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)

Exact text from the filing

February 4, 2026, Werewolf Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s co

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-041305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.